Articles On BOD Australia (ASX:BDA)

Cannabis centric healthcare company Bod Australia Limited (ASX:BDA) has announced the appointment of accomplished senior accounting and financial management executive Mr Alan Dworkin as Chief Financial Officer, effective 3rd May 2021. Mr Dw...

Source: Yarygin, Shutterstock Summary The Australian cannabis market is flourishing with growing patient numbers and better product selection. Medicinal cannabis player Bod Australia has won a new PO for CBD products for the US cannab...

The market continues its up and down ride, just have a look at what Dale Gillham says about it below, however there were a few small cap stocks that delivered decent news this week and saw the benefits. Here’s a few we’ve had our eye on. Bo...

Source: DG PhotoStock, Shutterstock Summary ASX-cannabis player Bod Australia has obtained a binding purchase order (PO) for CBD products in the US. Another cannabis player, MGC Pharmaceuticals, has completed the delivery of the first...

The Bod Australia Ltd (ASX: BDA) share price is on the run during early morning trade. This comes after the company announced its first purchased order for the United States market. At the time of writing, the cannabis healthcare company’s...

Medicinal cannabis, CBD and hemp healthcare products company, Bod Australia Limited (ASX:BDA) has received a maiden $312,000 binding purchase order from exclusive global partner, Health & Happiness Group Limited (HKSE: 1112) for CBD pro...

Medicinal cannabis and CBD and hemp healthcare products company, Bod Australia Limited (ASX:BDA) achieved record medicinal cannabis sales growth during the March quarter of fiscal 2021, filling 3789 MediCabilisTM prescriptions. This represe...

The Bod Australia Ltd [ASX:BDA] share price is down just over 1%, trading at 45.5 cents. The BDA shares caught the pot stock renaissance wave starting in October 2020 but have since settled... The post Bod Australia Share Price Down Despit...

Whilst some cannabis stocks can trade on hype and future earnings potential, Bod Australia (ASX: BDA) has much more than that going for it.

Source: Miss Nuchwara Tongrit, Shutterstock Summary Bod Australia has entered into a collaboration agreement with Drug Science UK to evaluate the effectiveness of MediCabilis®. Bod is confident that the deal could unlock significant m...

Bod Australia Limited (ASX:BDA) has entered into a collaboration agreement with the UK’s leading independent scientific body on drugs, Drug Science UK, which has the potential to unlock a large market opportunity for BDA in the treatment of...

Cannabis stock Bod Australia (ASX:BDA) has entered the fight against what is known as “long-COVID”.   What is ‘long-COVID’? “Long-COVID” occurs when people suffer COVID-19 symptoms for several weeks of months after the initial onset of symp...

Pot legalisation is creeping across the US state by state, and a major market could be about to join their ranks. Reports out of New York indicate that lawmakers in the Empire State are close to signing a new bill legalising recreational ca...

The past six months has seen a large global regulatory shift with regards to cannabis classification. In Australia, the Therapeutic Goods Administration (TGA) announced a decision to down schedule CBD products to Schedule 3 (Pharmacist Only...

Summary Broder economic recovery scenario, US market stimulus and rising bond yields has boosted investor's confidence in the share market.  December Retail turnover showed a growth of 9.6% over December 2019, according to ABS.  Retai...

The Bod Australia Ltd (ASX: BDA) share price is up more than 5% today following the release of a positive trading update. At the time of writing, shares in the cannabis healthcare company are trading 5.3% higher at 49.5 cents. What’s drivi...

Summary Bod Australia Ltd (ASX:BDA) reported a record total attributable sales of A$3.33 million for the quarter ended 31 December (Q2FY2021).  The record sales in the given period were supported by purchase orders from Bod’s exclusive...

At time of writing the Bod Australia Ltd [ASX:BDA] share price sits at 47.5 cents, up 10.47%. The company recently announced a large increase in sales in the second half of 2020. Bod Australia are a medicinal cannabis company... The post Bo...

The Bod Australia Ltd (ASX: BDA) share price is storming higher today as the company announced strong sales. Shares in the medicinal cannabis company have soared on the news, gaining 10.47%. As a result the Bod share price is currently tra...

BOD Australia Limited (ASX:BDA) announced that it achieved a substantial medicinal cannabis sales growth during 2H CY2020. During this period, the Company noted that 3,941 MediCabilis™ prescriptions were filled, up 91% compared to 1H CY2020...

In late morning trade the S&P/ASX 200 Index (ASX: XJO) has bounced back from yesterday’s weakness and is storming higher. At the time of writing, the benchmark index is up 1.25% to 6,690.3 points. Four shares that are climbing more tha...

Even without the benefit of an upcoming over-the-counter sales breakthrough for the medicinal cannabis industry, Bod Australia (ASX: BDA) managed to achieve significant growth in sales in the last six months of 2020. The Sydney-based purv...

07 Jan 2021 - Medicinal cannabis company, Bod Australia (ASX:BDA) has achieved strong sales growth during the second half of the 2020 calendar year.

The BOD Australia Ltd (ASX: BDA) share price is climbing higher on news the company has secured purchase orders for the Italian market. In midday trade, the Bod share price is up 5.7% at 46 cents. What did Bod announce? This morning, Bod a...

The BOD Australia Ltd (ASX: BDA) share price is on the run today following a positive update from the company regarding an uptick in sales. During the opening minutes of today’s market, shares in the cannabis healthcare company rose as hig...

The BOD Australia Ltd (ASX: BDA) share price was shooting higher as the company launched its CBD (cannabidiol) product in the Netherlands. By the market’s close, the BOD share price was trading 7.69% higher at 56 cents. The Australian micr...

ASX cannabis stocks are continuing their victory lap following yesterday’s decision by the TGA to re-classify low-dose cannabidiol (CBD) products. The TGA has made an interim decision to down schedule CBD products, including oil and pills,...

The BOD Australia Ltd (ASX: BDA) share price popped 8% today after the release of the company’s recent quarterly activities report, which outlines a record quarter of revenue growth. Bod shares have since pulled back slightly to be sitting...

Australian medicinal cannabis, CBD and hemp healthcare products company, Bod Australia (ASX:BDA) has reported record revenue of $2.5 million for the quarter ending 30 June 2020.

Our summary of BOD Australia Ltd's recent announcement What's happened? Bod Australia Ltd (ASX: BDA, “Bod”) advises that it has achieved strong revenue growth in recent months with FY2020 revenue now totalling ~$4.5m. What are the key highl...

Our summary of BOD Australia Ltd's recent announcement What's happened? Bod Australia Ltd (ASX: BDA, “Bod”) has advised that it is continuing to experience significant uptake of its MediCabilis™ product amongst Australian patients. What are...

Cannabis-focused healthcare company Bod Australia (ASX: BDA) has issued the first prescriptions for its MediCabilis product to UK patients participating in Europe’s largest medicinal cannabis registry. Project Twenty21 aims to generate the...

Medicinal cannabis, CBD and hemp healthcare products company, Bod Australia (ASX: BDA), has announced that prescriptions for its MediCabilis medicinal cannabis product have been received from UK patients participating in Project Twe...

Our summary of BOD Australia Ltd's recent announcement What's happened? Bod Australia Ltd (ASX: BDA, “Bod”) has confirmed first prescriptions of the Company’s MediCabilis™ medicinal cannabis product received from UK patients participating i...

It’s been a busy week for Bod Australia (ASX: BDA) with the company following up its first UK MediCabilis prescriptions with news it had received a record $1.43 million purchase order from Health and Happiness Group to sell its cannabinoid...

Our summary of BOD Australia Ltd's recent announcement What's happened? Bod Australia Ltd (ASX: BDA, “Bod”) has received a binding purchase order from Health & Happiness Group Ltd (H&H Group, HKSE: 1112) valued at $1.43m. What are t...

Medicinal cannabis company Bod Australia (ASX:BDA) says it has received its first prescriptions for MediCabilis from patients in the UK.

Our summary of BOD Australia Ltd's recent announcement What's happened? Bod Australia Ltd (ASX: BDA, “Bod”) has received its first prescriptions for MediCabilis™ from patients in the United Kingdom. What are the key highlights? The prescri...

The Australian drugs regulator is weighing whether to allow cannabidiol-only (CBD) products to be sold over the counter in pharmacies, bringing it into line with other countries where medical marijuana is legal. The Therapeutic Drug Adminis...

Our summary of BOD Australia Ltd's recent announcement What's happened? Bod Australia Ltd (ASX: BDA, “Bod”) have announced their Q3 FY2020 results, which showed a 135% increase in revenue on Q2 FY2020, to A$1.257m. What are the key highligh...

For months it seemed Avecho (ASX:AVE) was going to pot, figuratively, but now it is literally. Avecho has a patented drug delivery system called targeted penetration matrix (TPM) which is derived from vitamin E and enhances the solubility a...

New prescriptions are driving growth for medicinal cannabis company Bod Australia (ASX: BDA) while a recent launch for hemp products with Swisse Wellness has been well received. The Sydney-based group saw its revenue jump by 144 per cent...

Nine months after he resigned as CEO and three months after quitting as chief innovation officer, Elixinol (ASX:EXL) founder Paul Benhaim is back as chairman. He replaces Andrew Duff, who chaired the company from its 2018 ASX listing, and G...

Our summary of Scidev Ltd's recent announcement What's happened? SciDev Ltd (ASX: BDA, “SciDev”) have announced it has achieved month of March sales of AUD$4.8M. What are the key highlights? Sales volumes were spread across mining, oil &am...

Our summary of BOD Australia Ltd's recent announcement What's happened? Bod Australia Ltd (ASX: BDA, “Bod”) have announced that it has launched nine hemp-based products for the Australian market with supplements and skincare brand Swisse We...

Rapid medicinal cannabis prescriptions growth, new product launches and a UK expansion have lifted Bod Australia's (ASX: BDA) performance in the first half of FY20. The Sydney-based company saw its revenue almost double to $2.09 million,...

What's happened? Bod Australia Limited (ASX:BDA, "Bod") released its financial results for 1H FY2020. What are the key highlights? Revenue up 94.5% on PCP to nearly $2.1m. $7m transformational investment from NewH2 and exclusive global agr...

Medicinal cannabis producer Bod (ASX: BDA) is off to a strong start in 2020, reporting January as its third-largest month on record. The group filled 373 prescriptions of its MediCabilis during the month, bringing the total number of pres...

What's happened? Bod Australia Limited (“Bod”, ASX: BDA) reported a strong start to MediCabilis™ prescription sales in 2020 with 373 prescriptions filled in January, the third largest month on record. What are the details? Bod has now fille...

Cannabis healthcare company Bod Australia (BDA) will expand its medicinal CBD range after receiving an import permit Two new crystalline isolate products, delivered as a solid or powdered form of CBD, will become part of Bod’s offering The...